Up-to-date List of Ezetrol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Ezetrol Medical Research Studies

1 Unknown  Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Conditions: Hypercholesterolemia;   HIV Infections
Interventions: Drug: Ezetimibe;   Drug: Rosuvastatin (standard care)
Outcome Measures: The primary endpoint is the difference in final value of serum apolipoprotein B between participants treated with rosuvastatin versus participants treated with both rosuvastatin and ezetimibe.;   Percent change in apolipoprotein B, percent and absolute change total cholesterol, LDL, HDL, triglycerides, apolipoprotein A1, apolipoproteinB/apoliporoteinA1 ratio and C-reactive protein;   Assessment of safety parameters, specifically incidence of complications as measured by an increase in AST &/or ALT ≥3-fold ULN & a CK ≥10-fold ULN
2 Unknown  Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
Condition: Atherosclerosis
Interventions: Drug: Ezetrol (Ezetimibe);   Drug: Vytorin (Ezetimibe + Simvastatin)
Outcome Measure: The difference of FDG uptake quantified by measuring the standardized uptake value (SUV) corrected for body weight according to the treatment groups
3 Unknown  Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.
Condition: ST-Segment Elevation Myocardial Infarction
Interventions: Drug: Ezetimibe;   Drug: Placebo
Outcome Measures: Plaque volume and composition in a non-significant coronary plaque;   Change in plaque-composition (measured with Tissue Characterization) in a 10 mm segment of a native coronary vessel with a non-significant stenosis where plaque-volume at baseline is greatest.;   Change in percent of the plaque volume in the native coronary vessel with a non-significant stenosis.;   Change in percent of the plaque volume in the 10 mm segment of a native coronary vessel with a non-significant lesion where plaque volume at baseline is greatest.;   Change in absolute numbers of the plaque volume in the 10 mm segment of a native coronary vessel with a non-significant lesion where plaque volume at baseline is greatest.;   Change in percent of the plaque burden in the 10 mm segment of a native coronary vessel with a non-significant lesion where plaque volume at baseline is greatest.;   Change in percent of the plaque burden in a native coronary vessel with a non-significant lesion.;   Incomplete stent apposition.;   Edge response in stented segment.;   Stent expansion.;   Evaluation of the OCT-technique in clinical use compared to IVUS.;   Evaluation of the Resolute stents effect on neointima growth and apposition.
4 Not yet recruiting Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe
Condition: Dyslipidemia
Interventions: Drug: NVP-1205;   Drug: rosuvastatin+ezetimibe
Outcome Measures: AUClast;   AUCinf
5 Recruiting Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
Condition: Metabolic Syndrome X
Interventions: Drug: Ezetimibe;   Drug: Placebo
Outcome Measures: Change in intestinal mRNA expression levels of LDL receptor between the two 12-week interventions;   Change in intestinal protein mass levels of LDL receptor between the two 12-week interventions;   Change in intestinal mRNA expression levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA reductase between the two 12-week interventions;   Change in intestinal protein mass levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA reductase between the two 12-week interventions
6 Unknown  Atorvastatin Plus Ezetimibe on Coronary Plaque Progression
Condition: Coronary Artery Disease
Interventions: Drug: atorvastatin;   Drug: atorvastatin plus ezetimibe
Outcome Measures: change of coronary artery plaque volume;   composite of adverse cardiac events
7 Not yet recruiting Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients
Condition: Coronary Artery Disease
Interventions: Drug: Ezetimibe;   Dietary Supplement: Nutraceuticals
Outcome Measures: Reasons for treatment discontinuation;   Effects on lipid profile
8 Recruiting Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients
Condition: Coronary Artery Disease
Interventions: Drug: Ezetimibe;   Drug: Nutraceuticals
Outcome Measures: Evaluation of treatment tolerability;   Evaluation of drug effects on lipid and metabolic features
9 Recruiting Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection
Condition: Chronic Hepatitis C
Intervention: Drug: Ezetimibe
Outcome Measures: HCV plasma viral load;   HCV biliary viral load
10 Unknown  Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe
Condition: Heterozigous Familial Hypercholesterolemia
Intervention: Drug: Statins and Ezetimibe
Outcome Measures: Evaluate if there is any correlation among the reduction of the plasma clearance of chylomicrons by the artificial chylomicrons technique and the presence of sub-clinical atherosclerosis;   Evaluate if ezetimibe/simvastatin enhances the effects of simvastatin alone in the removal of chylomicrons in patients with HF.
11 Unknown  Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe
Condition: Endothelial Function
Intervention: Drug: simvastatin, combined with simvastatin ezetimibe, placebo
Outcome Measures: Percent change vasodilation of brachial artery flow-mediated, after eight weeks of treatment.;   biochemical markers
12 Unknown  Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
Condition: Metabolic Syndrome
Interventions: Drug: Simvastatin;   Drug: Vytorin;   Drug: Placebo;   Drug: Ezetimibe
Outcome Measures: To identify the common factor for L5 prevalence in Metabolic Syndrome patients.;   To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome.
13 Not yet recruiting Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe
Condition: Healthy
Outcome Measures: Rosuvastatin AUCτ,ss;   Rosuvastatin Cmax,ss;   Ezetimibe Cmax,ss;   Ezetimibe AUCτ,ss;   Rosuvastatin Tmax,ss;   Rosuvastatin t1/2β;   Ezetimibe Tmax,ss;   Ezetimibe t1/2β
14 Unknown  A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
Conditions: Hyperlipidemia;   Hypercholesterolemia
Interventions: Drug: ezetimibe;   Drug: niacin;   Drug: colestipol
Outcome Measures: To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. The patient’s cardiovascular risks are assessed to determine i;   . Secondary measures examine the safety issues with liver function test (LFT) monitoring and rhabdomyolysis. High-density lipoproteins (HDL) elevations are monitored between the three groups to determine efficacy as a secondary outcome.
15 Recruiting Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
Condition: Non Alcoholic Steatohepatitis
Intervention: Drug: Ezetimibe
Outcome Measure: Liver Biopsy
16 Recruiting Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
Condition: Hypercholesterolemia
Interventions: Drug: ETC-1002;   Drug: Ezetimibe
Outcome Measures: Percent change in calculated low density lipoprotein-cholesterol (LDL-C);   Percent change in other lipid measures non high density lipoprotein cholesterol (nonHDL-C);   Safety using adverse event reports; vital signs;   Percent change in Apolipoprotein B (ApoB);   Percent change in high sensitivity C-reactive protein (hsCRP);   Safety using adverse event reports; clinical laboratory results;   Safety using adverse event reports; rates of muscle-related adverse
17 Not yet recruiting The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients
Conditions: Dyslipidemia;   Transplants
Intervention: Drug: Ezetimibe
Outcome Measures: Decrease of LDL cholesterol concentration.;   Change in oxidative markers
18 Unknown  Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia
Condition: Hypercholesterolemia
Interventions: Drug: Rosuvastatin;   Drug: Ezetimibe
Outcome Measures: Low-density lipoprotein (LDL) cholesterol;   The ability to remain on Crestor for the study period
19 Unknown  Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
Conditions: HIV;   Hyperlipidemia;   HIV Infections
Interventions: Drug: ezetimibe;   Drug: fenofibrate;   Drug: pravastatin
Outcome Measure: per cent changes of LDL cholesterol, comparison between the 2 treatment regimens
20 Unknown  Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Interventions: Drug: Rosuvastatin + Ezetimibe;   Drug: Simvastatin + Ezetimibe
Outcome Measures: Changes in LDL-Cholesterol level;   Changes in HDL, triglycerides and apolipoprotein B levels;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.

These studies may lead to new treatments and are adding insight into Ezetrol etiology and treatment.

A major focus of Ezetrol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Ezetrol

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us